ArticleFrontiers in oncology2026
Prostatic malakoplakia: a rare case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malakoplakia is an extremely rare chronic inflammatory disorder, most commonly affecting the genitourinary tract. Prostatic malakoplakia is particularly uncommon. Its elevated serum prostate-specific antigen (PSA) levels, magnetic resonance imaging (MRI) findings, and clinical symptoms closely mimic those of prostate cancer, leading to a high risk of misdiagnosis. Here we report a 64-year-old male patient presenting with gross hematuria, frequency, and urgency. Laboratory tests revealed elevated inflammatory markers and a serum PSA of 8.72 ng/mL. Multiparametric MRI (mpMRI) showed a Prostate Imaging Reporting and Data System (PI-RADS) score of 4, raising high suspicion of prostate cancer. Transrectal ultrasound-guided prostate biopsy was performed. Histopathology showed diffuse infiltration by histiocytes containing characteristic Michaelis-Gutmann (MG) bodies with typical morphological features on hematoxylin and eosin (H&E) staining. Immunohistochemistry confirmed prostatic malakoplakia and ruled out malignancy. After treatment with piperacillin sodium, the patient's symptoms resolved completely. Follow-up at one month showed normalization of inflammatory markers and PSA. This article also narrative literature review 90 cases reported in the past 30 years, summarizing the clinical presentation, imaging features, pathological characteristics, diagnosis, differential diagnosis, and treatment strategies for prostatic malakoplakia. In patients with elevated PSA and mpMRI findings suspicious for prostate cancer, if the lesion shows diffuse symmetric distribution, an intact capsule, and delayed periprostatic enhancement, prostatic malakoplakia should be included in the differential diagnosis. Definitive diagnosis depends on pathological identification of MG bodies. Antibiotic therapy appears to be effective in most reported cases, and the prognosis is generally favorable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.